Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Bironzo, P;Novello, S;
2019-01-01

Abstract

Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.
2019
///
///
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389252/
Immunotherapy-lung cancer-oncogenic addiction
Mazières, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C; Couraud, S; Veillon, R; Van Den Heuvel, M; Neal, J; Pel...espandi
File in questo prodotto:
File Dimensione Formato  
mdz167.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 2.17 MB
Formato Adobe PDF
2.17 MB Adobe PDF Visualizza/Apri
1-s2.0-S0923753419312840-main.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 515.73 kB
Formato Adobe PDF
515.73 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1703925
Citazioni
  • ???jsp.display-item.citation.pmc??? 270
  • Scopus 902
  • ???jsp.display-item.citation.isi??? 830
social impact